2BO
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 … Read more
2BO (2BO) - Total Liabilities
Latest total liabilities as of September 2025: €10.82 Million EUR
Based on the latest financial reports, 2BO (2BO) has total liabilities worth €10.82 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
2BO - Total Liabilities Trend (2021–2024)
This chart illustrates how 2BO's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
2BO Competitors by Total Liabilities
The table below lists competitors of 2BO ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zodiac Clothing Company Limited
NSE:ZODIACLOTH
|
India | ₹1.63 Billion |
|
Regal Hotels International Holdings Limited
F:RH6B
|
Germany | €16.76 Billion |
|
Sleep Cycle AB
ST:SLEEP
|
Sweden | Skr128.31 Million |
|
Ginni Filaments Limited
NSE:GINNIFILA
|
India | ₹862.14 Million |
|
Coronation Fund Managers Ltd
JSE:CML
|
South Africa | ZAC97.55 Billion |
|
Eagle Plains Resources Ltd
PINK:EGPLF
|
USA | $1.85 Million |
|
PannErgy Nyrt.
F:PPL
|
Germany | €14.92 Billion |
|
Ikonisys SA
PA:ALIKO
|
France | €7.50 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down 2BO's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 6.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.87 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 2BO's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 2BO (2021–2024)
The table below shows the annual total liabilities of 2BO from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €6.22 Million | -84.94% |
| 2023-12-31 | €41.26 Million | +6.80% |
| 2022-12-31 | €38.64 Million | +4.56% |
| 2021-12-31 | €36.95 Million | -- |